Other anti-CD20 compounds include Ocrelizumab a recombinant, humanized anti-CD20 mAb that is approved for the treatment of primary progressive and relapsing multiple sclerosis, and ofatumumab, a cytolytic IgG1k fully human monoclonal antibody approved for the treatment of Chronic Lymphocytic Leukemia (47). This evidence concerns the gene MS4A1 and B-cell chronic lymphocytic leukemia.